Investors & Media Press Releases

Press Releases

Summary Toggle

01.03.2019

Summary Toggle Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones

Summary ToggleAxovant’s CEO, Pavan Cheruvu, M.D., will be presenting at the J.P. Morgan Healthcare Conference at 8:00 a.m. PST on Thursday, January 10 th , 2019 Initial clinical data expected in first half of 2019 from the AXO-AAV-GM2 and AXO-Lenti-PD gene therapy programs Axovant assembles Scientific Advisory
Read More

PDF Version
Read More
Summary Toggle

12.14.2018

Summary Toggle Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

Summary ToggleBASEL, Switzerland , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross proceeds to Axovant from the offering are expected
Read More

PDF Version
Read More
Summary Toggle

12.13.2018

Summary Toggle Axovant Sciences Announces Public Offering of Common Shares

Summary ToggleBASEL, Switzerland , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to
Read More

PDF Version
Read More
Summary Toggle

12.13.2018

Summary Toggle Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School

Summary ToggleTwo novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipeline AXO-AAV-GM1 expected to enter the clinic in first half 2019, with initial data expected in second half 2019 First patient has been dosed with AXO-AAV-GM2, with initial data expected in first quarter
Read More

PDF Version
Read More
Summary Toggle

12.10.2018

Summary Toggle Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder

Summary TogglePrimary efficacy endpoint assessed by sleep laboratory video assessment was not met Axovant is discontinuing clinical development of nelotanserin BASEL, Switzerland , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, today reported topline
Read More

PDF Version
Read More
Summary Toggle

12.06.2018

Summary Toggle Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial

Summary ToggleMeeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD Confirmed with FDA that the proposed current manufacturing process and quality control testing is adequate for the clinical program
Read More

PDF Version
Read More
Summary Toggle

11.26.2018

Summary Toggle Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline

Summary ToggleGreg MacMichael , Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis , joins Axovant as SVP of technical operations Parag Meswani , Pharm.D., formerly head of U.S. marketing and diagnostics at Spark Therapeutics , joins Axovant as SVP of
Read More

PDF Version
Read More
Summary Toggle

11.07.2018

Summary Toggle Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates

Summary ToggleFirst patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s disease Expanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy (OPMD) and collaboration agreement for five additional
Read More

PDF Version
Read More
Summary Toggle

10.25.2018

Summary Toggle Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

Summary ToggleInitial data from the first cohort expected in first half of 2019 BASEL, Switzerland , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in a
Read More

PDF Version
Read More
Summary Toggle

10.09.2018

Summary Toggle Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy

Summary ToggleBASEL, Switzerland , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases, today announced upcoming presentations regarding its investigational gene therapy programs,
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search